Full-Time

GL Accountant

Confirmed live in the last 24 hours

BillionToOne

BillionToOne

501-1,000 employees

Molecular diagnostics for prenatal and oncology testing

Compensation Overview

$104k - $124.8k/yr

+ Corporate Bonus Program + Equity Options

Mid, Senior

Menlo Park, CA, USA

Hybrid

This is a hybrid position.

Category
Financial Accounting
Management Accounting
Accounting
Required Skills
NetSuite
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Accounting, Finance or Economics
  • 3-5 years of public accounting experience required, preferably at a publicly traded company.
  • Proficiency with NetSuite strongly preferred, advanced Excel skills and familiarity with GAAP.
  • Experience in system implementation and process improvement initiatives.
  • Strong analytical and data-driven decision-making skills with strong attention to detail.
  • Self-motivated, deadline driven and results oriented; a problem solver with strong teamwork skills and strong desire to drive change.
  • Proven ability to manage multiple tasks, prioritize workload effectively, and meet tight deadlines.
  • Excellent verbal and written communication skills for collaboration with cross-functional teams and presentation of financial findings.
Responsibilities
  • Prepare month-end close journal entries, accruals, account reconciliations, and financial analyses across various functional areas, including but not limited to: cash, investments, prepaid expenses, use tax, fixed assets, accounts payable, accrued liabilities. Ensure all entries are accurate and properly classified. Investigate and resolve discrepancies promptly.
  • Monitor daily cash activity and support short-term cash forecasting to support business needs.
  • Manage the fixed asset lifecycle, including capitalization, disposals, depreciation schedules, and ensuring proper classification in accordance with company policy and GAAP.
  • Prepare, review, and maintain supporting documentation, perform monthly and quarterly flux analyses of financial accounts and statements.
  • Uphold and enforce established internal control procedures, ensuring that accounting processes adhere to company policies and accounting standards.
  • Collaborate with the procurement and supply chain teams to ensure effective use of the purchase order (PO) process. Support vendor setup and assigned purchase orders responsibilities.
  • Prepare audit schedules, documentation and support external audits during quarter-end and year-end close. Address inquiries or requirements in a timely manner.
  • Contribute to ad-hoc projects, process improvements, and system enhancements to optimize accounting operations and data accuracy.

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to enhance healthcare outcomes through precise testing and to foster a culture of growth, equality, and teamwork.

Company Size

501-1,000

Company Stage

Series D

Total Funding

$425.9M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne achieved 100% accuracy in non-invasive fetal RhD detection in the US.
  • The company reached a milestone of 1 million UNITY tests, indicating strong market presence.
  • BillionToOne's revenue doubled in 2024, driven by prenatal testing success.

What critics are saying

  • Increased competition in molecular diagnostics could threaten BillionToOne's market share.
  • Rapid technological advancements may require continuous innovation, straining resources.
  • Economic instability in target markets could limit growth for affordable prenatal testing.

What makes BillionToOne unique

  • BillionToOne's QCT technology offers single-molecule precision in DNA counting.
  • UNITY test is the only non-invasive prenatal screen for recessive conditions without a male sample.
  • Northstar products provide personalized oncology testing, enhancing treatment decisions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Femtech Insider
May 16th, 2025
BillionToOne Expands Prenatal Test to Screen for 14 Genetic Conditions from Single Maternal Blood Sample

Molecular diagnostics company BillionToOne has launched an expanded version of its UNITY Fetal Risk Screen that can assess fetal risk for up to 14 genetic conditions from a single maternal blood sample as early as nine weeks into pregnancy.

BillionToOne
May 15th, 2025
BillionToOne Expands Executive Team with Dr. Haywood Brown as Chief Medical Officer, Prenatal

Dr. Brown joins BillionToOne as the company has recently celebrated the milestone of 1 million UNITY tests.

PR Newswire
Apr 25th, 2025
Billiontoone To Present New Data At Aacr Annual Meeting 2025

Innovations in liquid biopsy technology demonstrate a more accurate method to infer in-tissue copy number from ctDNA, detection of a novel non-tumor derived pseudogene of GNA11, and development of an epigenetic-based method for precise tumor burden measurementMENLO PARK, Calif., April 25, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests accessible to all, announced today several abstract presentations that will be showcased at the American Association of Cancer Research (AACR) Annual Meeting on April 25–30, 2025, in Chicago, IL.Each abstract highlights BillionToOne's relentless focus in advancing the field of liquid biopsy technology:Title: "Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay"Session Time: 4/29/25 at 9:00 AM - 12:00 PMLocation: Poster Section 20Title: "Detection of a novel GNA11 processed pseudogene from cfDNA and implications for liquid biopsy"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 31Title: "Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 32"These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be achieved with plasma-based tests," said Dr. Gary Palmer, Chief Medical Officer, Oncology at BillionToOne. "Together, these innovations enhance the accuracy and robustness of ctDNA-based cancer profiling and monitoring, which will ultimately enable more precise treatment decisions for patients."About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, is the only multiplex methodology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com .Media Contact: [email protected]SOURCE BillionToOne

Trade Show News
Apr 25th, 2025
BillionToOne to Present New Data at AACR Annual Meeting 2025

BillionToOne to present new data at AACR Annual Meeting 2025.

PR Newswire
Mar 18th, 2025
Billiontoone Celebrates Major Milestone: 1 Million Unity Tests

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.MENLO PARK, Calif., March 18, 2025 /PRNewswire/ -- BillionToOne, Inc. , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a significant milestone of conducting one million UNITY prenatal tests. This achievement highlights the company's exceptional execution and superior product differentiation, which has fueled remarkable year-over-year growth and established BillionToOne as a leading player in the U.S. prenatal testing market.Powered by BillionToOne's patented Quantitative Counting Template™ (QCT™) molecular counting technology, the UNITY Fetal Risk Screen™ stands apart as the only prenatal genetic test that directly assesses a baby's risk for recessively inherited conditions, including cystic fibrosis, spinal muscular atrophy (SMA), and sickle cell disease, without requiring a male partner's sample or invasive testing."Surpassing 1 million UNITY tests in only 5 years is not just a milestone for our company, but a testament to how our technology is transforming prenatal care," said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. "What is more impressive is that our annual run-rate is already above 500,000 UNITY tests this year, indicating truly exponential growth and establishment of UNITY as the next standard in prenatal care. This achievement would not be possible without the dedication of our employees, the support of our partners, and the trust of our healthcare providers."BillionToOne has firmly established itself as the fastest-growing molecular diagnostics laboratory, with 100% year-over-year revenue growth in 2024.This milestone further solidifies BillionToOne's position as a leading provider in democratizing access to essential prenatal testing, particularly for those who need it most